Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
IPO Year: 2020
Exchange: AMEX
Website: annovisbio.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/29/2023 | $36.00 | Buy | Canaccord Genuity |
7/7/2021 | $45.00 → $150.00 | Buy | Maxim Group |
Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00
Maxim Group reiterated coverage of Annovis Bio with a rating of Buy and set a new price target of $150.00 from $45.00 previously
Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct
SC 13G/A - Annovis Bio, Inc. (0001477845) (Subject)
SC 13G - Annovis Bio, Inc. (0001477845) (Subject)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
10-Q - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
S-8 - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4/A - Annovis Bio, Inc. (0001477845) (Issuer)
4/A - Annovis Bio, Inc. (0001477845) (Issuer)
4/A - Annovis Bio, Inc. (0001477845) (Issuer)
4/A - Annovis Bio, Inc. (0001477845) (Issuer)
4/A - Annovis Bio, Inc. (0001477845) (Issuer)
BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced the appointment of Andrew Walsh as VP, Finance. "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer's and Parkinson's clinical trials in 2024. The addition of Andrew Walsh to our team marks another step in our growth plans," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Andrew brings 12 years of extensive experience in finance operations, adding a
TheracosBio today announced the appointment of former US Congressman Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty, MBA, as its Chief Financial Officer. Congressman Greenwood is an established leader in life sciences across business and public policy, and Mr. McGroarty has served as a CFO of public and private life sciences and technology companies. Both newly appointed team members will help shape the commercial strategy for Brenzavvy™ (bexagliflozin), a recently FDA-approved treatment for type 2 diabetes. "Accomplished leaders, Jim and Jeff will be valuable members of our team at this critical time for TheracosBio," said Albert R. Collinson, Ph.D., Pres
BERWYN, Penn., Nov. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced third quarter financial results for the quarter ended September 30, 2022, and reviewed recent accomplishments. Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented: "This quarter, we have made significant advances in the clinical development of buntanetap as we began to dose patients in our Phase 3 trial for early Parkinson's Disease and received FDA author
BERWYN, Pa., Aug. 29, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately. Mr. Hagopian comes to Annovis with 30 years of finance and accounting experience, including 15 years of increasing responsibility at Organogenesis, a leading publicly-traded regenerative medicine company. The company has also announced that Jeff McGroarty has stepped away from his role as Chief Financial Officer to pursue other interests. Mr. McGroarty will assist in an orderly transition of his duties over the ne
Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced first quarter financial results for the quarter ended March 31, 2022, and provided a corporate update.Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented, "we have made significant progress advancing buntanetap in Parkinson's disease and Alzheimer's disease this quarter. We received positive feedback from the U.S. Food and Drug Administration (FDA) for two Phase 3 clinical trials with buntanetap in early and late Parkinson's disease. As our clinical trials ad
Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory OperationsCompany Promotes Cheng Fang, Ph.D., to Senior Vice President of Research & DevelopmentBerwyn, Pennsylvania--(Newsfile Corp. - January 10, 2022) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the appointment of Eve Damiano, MS, RAC, as its new Senior Vice President of Regulatory Operations, and the promotion of Cheng Fang, Ph.D., to Senior Vice President of Research & Development, as of January 1, 2022."We are all delighted to welcome Ms. Damiano to our diverse team of highly motivated industry expe
Dr. Fang has authored 15 published papers including two on axonal transport and several on protein aggregationBerwyn, Pennsylvania--(Newsfile Corp. - May 18, 2021) - Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the appointment of Cheng Fang, Ph.D., as its new Vice President of Research."I am excited to welcome Dr. Fang to Annovis Bio. Her knowledge of research in our field, as well as in general, is excellent," commented Maria Maccecchini, Ph.D., CEO of Annovis Bio. "She will be instrumental in furthering our work on the mechanism of action of our drug
Berwyn, Pennsylvania--(Newsfile Corp. - April 15, 2021) - Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the appointment of Reid S. McCarthy to its Board of Directors and to the role of Audit Committee chairman, effective April 9, 2021.A specialist in bank, bond, and equity financings, McCarthy retired after serving from 2016 to 2019 as CFO of JJ Haines & Company, Inc., a $400 million revenue distribution company operating internationally. Previously, McCarthy provided CFO consulting services to several life sciences companies, served as CFO of Topaz Pharm
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs. This strategic approach holds promise for providing hope to millions of patients suffering from historically challenging diseases. Alzheimer's disease (AD) for example, has become a focal point of this innovation, with recent U.S. Food and Drug Administration (FDA) approvals of Leqembi and Kisunla — although these treatments only slow cognitive decline rather than improve cognitive function. New uses for approved glucagon-like pept
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE:ANVS) announces the availability of a broadcast titled, "Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition." To hear the AudioPressRelease, please visit: The NetworkNewsAudio To view the full editorial, please visit: https://nnw.fm/ZIUid Annovis Bio Inc. is at the forefront of the movement to develop new safe and effective drugs for neurodegenerative diseases, including AD. The company has long pursued the goal to improve the health of nerve cells and, in the process, improve cognition in neurodegenerative disorders. The company's lead drug candidate, buntanetap
NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE:ANVS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, "Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition," please visit: https://nnw.fm/ZIUid Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have r
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (FDA) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer's. However, th
MALVERN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the filing of three new patents for innovative combination therapies involving its lead compound, buntanetap. These patents cover combinations of buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), or a combination of all three, creating a multifaceted approach to treating neurodegenerative diseases. Buntanetap, the Company's lead drug asset, inhibits the production of neurot
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, held both virtually and in person at the Lotte New York Palace Hotel in New York City, September 9-11, 2024. Event Details Company Presentation: Date: Tuesday, September 10, 2024Time: 8:00 - 8:30 a.m. Eastern Time (ET) Panel Participation: Topic: "Non-amyloid Approaches in Al
MALVERN, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced financial results for the second quarter ended June 30, 2024, and provided a business update. "The recent months have been productive for our company," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio. "We've completed pivotal Phase 2/3 Alzheimer's and Phase 3 Parkinson's studies, both of which revealed very encouraging data for buntanetap. Additionally, we've introduc
MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity®) in a mouse model of Alzheimer's disease. GLP-1 agonists, commonly used to treat diabetes, weight loss, and heart conditions, are now showing promising potential in the treatment of Alzheimer's disease. Recent
LOS ANGELES, Aug. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast, recorded live from the Alzheimer's Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN's ongoing efforts to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell's latest podcast features Dr. Maria Maccecchini, Ph.D., Founder, Preside
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the issuance of a U.S. patent for methods of treating acute traumatic brain injuries (TBI) with its lead drug candidate, buntanetap. In 2016, the Company filed a patent covering the treatment of various nerve insults, including TBI, stroke, and nerve and spinal cord injuries. While these claims were granted in Europe and worldwide, the U.S. Patent and Trademark Office (
Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the issuance of a U.S. patent for methods of treating acute traumatic brain injuries (TBI) with its lead drug candidate, buntanetap.In 2016, the Company filed a patent covering the treatment of various nerve insults, including TBI, stroke, and nerve and spinal cord injuries. While these claims were granted in Europe and worldwide, the U.S. Patent and Trademark Office (USPTO) required the claims to be divided into individual patents for each indic
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $30 price target.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley cut the price target for Microchip Technology Incorporated (NASDAQ:MCHP) from $102 to $100. Morgan Stanley analyst Joseph Moore downgraded the stock from Overweight to Equal-Weight. Microchip Technology shares rose 3.9% to close at $95.98 on Wednesday. See how other analysts view this stock. Truist Securities lifted the price target for Astrana Health, Inc. (NASDAQ:ASTH) from $44 to $50. Truist Securities analyst Jailendra Singh upgraded the stock from Hold to Buy. Astrana Health sha
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy and raises the price target from $23 to $30.
Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 million registered direct offering of 947,868 shares at $10.55 per share. SeaStar Medical shares dipped 34% to $8.55 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) shares jumped 139% to $2.78 after the company announced results for a Swine Model pilot study for Probudur. Kazia Therapeutics Limited (NASDAQ:KZIA) gained 129% to $0.4325 after the company announced results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family reasons, effective July 5, 2024. NIO shares dipped 8.5% to $4.4550 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Qualigen Therapeutics, Inc. (NASDAQ:QLGN) jumped 120% to $0.3870 after gaining 6% on Wednesday. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) rose 70.5% to $4.65 after gaining around 14% on Wednesday. MediWound Ltd. (NASDAQ:MDWD) shares jumped 45.6% to $21.12 after dipping around 7% on Wednesday. Koss Corporation (NASDAQ:KOSS) shares climb